EUVIMEDEUVIMED entdecken
Open Access

Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes

Tao Zhang, Na Niu, Tamar Taddei, Dhanpat Jain iD, Xuchen Zhang

American Journal of Clinical Pathology · 2025

DOI: 10.1093/ajcp/aqae136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Tao Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Yale Liver Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Steatohepatitic hepatocellular carcinoma (SH-HCC) is currently recognized as a distinct histologic subtype of HCC. The prognosis and specific criteria for determining the amount of steatohepatitis required to define SH-HCC are still unclear.

Methods

After excluding all recognized HCC subtypes from 505 HCC cases (2010-2019), the remaining cases were categorized as conventional HCC (CV-HCC) (n = 223). The cases classified as SH-HCC (n = 171) were further divided into groups based on the percentage of steatohepatitis: 5% or more, 30% or more, and 50% or more.

Results

Hepatitis C virus infection was the predominant underlying liver disease in both the CV-HCC and SH-HCC groups. Metabolic dysfunction-associated steatotic liver disease (formerly nonalcoholic fatty liver disease) was more prevalent in all cases of SH-HCC with different steatohepatitic cutoffs than in cases of CV-HCC. There were no differences in the stage of fibrosis of the background liver between the CV-HCC and SH-HCC groups. SH-HCC with different cutoffs exhibited a notable increase in the presence of glycogenated nuclei, Mallory-Denk bodies, and hyaline globules in tumor cells. Survival analysis did not reveal substantial differences in overall survival between the CV-HCC and SH-HCC groups and among patients with SH-HCC with different steatohepatitis cutoffs.

Conclusions

The degree of intratumoral steatohepatitis in patients with SH-HCC does not appear to be a notable prognostic factor. The presence of steatohepatitis in the tumor is better recognized as 1 of the histopathologic patterns of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseFatty LiverHumansMaleFemaleMiddle AgedPrognosisAgedAdultRetrospective StudiesHepatitis C

Stichwörter der Autor:innen

hepatocellular carcinomapathologysteatohepatitic hepatocellular carcinomasteatohepatitis

Autor:innen und Institutionen

  • Department of Pathology.
  • Section of Digestive Diseases. Yale University School of Medicine. New Haven, CT, US.

ORCID-Profile: Dhanpat Jain

Förderung

  • NIDDK NIH HHS
  • Yale Liver Center

Zitieren

APA

Zhang, T., Niu, N., Taddei, T., Jain, D., & Zhang, X. (2025). Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae136

Vancouver

Zhang T, Niu N, Taddei T, Jain D, Zhang X. Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae136

BibTeX
@article{Zhang2025,
  author = {Zhang, Tao and Niu, Na and Taddei, Tamar and Jain, Dhanpat and Zhang, Xuchen},
  title = {Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  doi = {10.1093/ajcp/aqae136}
}
Kostenlos starten →